Qiagen (NYSE:QGEN) Issues FY25 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY25 earnings guidance on Monday morning. The company provided earnings per share guidance of ~$2.35 for the period, compared to the consensus earnings per share estimate of $2.27. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Wall Street Analysts Forecast Growth

QGEN has been the subject of several research analyst reports. Robert W. Baird downgraded Qiagen from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $52.00 to $42.00 in a research report on Wednesday, February 19th. UBS Group lowered their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Redburn Atlantic lowered shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and an average price target of $47.71.

Qiagen Stock Performance

Shares of QGEN stock opened at $38.24 on Monday. The company’s 50 day moving average is $40.27 and its 200 day moving average is $41.94. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The firm has a market cap of $8.50 billion, a price-to-earnings ratio of 106.48, a PEG ratio of 2.39 and a beta of 0.62. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. On average, sell-side analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.